Clinical Trial Update: Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Sanofi is conducting a Phase 3 non-inferiority trial comparing subcutaneous Frexalimab to intravenous administration in adults with multiple sclerosis; patient …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Frexalimab (SAR441344)

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 3 | Status: RECRUITING